This says to me that revenue might be closer than we think. As...

First 21 Last

Share
Profile

Follow
showie

644 Posts.

81

25/08/22

14:52

Post #: 63321763
Share

Originally posted by Maltsy: ↑

Page 3, Section 1:

the Bridging Loan (defined below) entered into between ResApp and Pfizer Australia to
provide for ResApp’s short-term working capital needs during the extended Scheme period;
.....
Importantly, ResApp Shareholders are advised that if the Scheme is not implemented by
23 September 2022, the current indicative Implementation Date, and the Scheme Implementation
Deed is terminated, ResApp will be required to immediately secure external funding to repay the
Bridging Loan (defined below) and to continue to fund ordinary further business activities.

The Board believes it will be able to raise the required funds on the equity capital market, albeit
potentially at a significant discount to the prevailing share price, and in this regard notes that it has
its full placement capacity under Listing Rule 7.1 available to facilitate a prompt placement of Shares
to one or more third parties. The Board is also investigating alternative financing arrangements,
including the borrowing of money against the future receipt of any tax rebates.

Expand

This says to me that revenue might be closer than we think. As it is not a solution to RAPs capital requirements at current cash burn vs. incoming revenue.

There's been a long silence since Pfizer began co-developing the covid screening app. Maybe we are on to something.

How has this screening APP not been sold to lifeworks, etc EAPs

RAP Price at posting: 18.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

HXL

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

AAI

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

OPL

Opyl forms JV with UK and US consortium to bring products to the world

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement